Zhao, J.J.; Fong, K.Y.; Chan, Y.H.; Tey, J.; Dawood, S.; Lee, S.C.; Finn, R.S.; Sundar, R.; Lim, J.S.J.
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers 2023, 15, 4558.
https://doi.org/10.3390/cancers15184558
AMA Style
Zhao JJ, Fong KY, Chan YH, Tey J, Dawood S, Lee SC, Finn RS, Sundar R, Lim JSJ.
Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers. 2023; 15(18):4558.
https://doi.org/10.3390/cancers15184558
Chicago/Turabian Style
Zhao, Joseph J., Khi Yung Fong, Yiong Huak Chan, Jeremy Tey, Shaheenah Dawood, Soo Chin Lee, Richard S. Finn, Raghav Sundar, and Joline S. J. Lim.
2023. "Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer" Cancers 15, no. 18: 4558.
https://doi.org/10.3390/cancers15184558
APA Style
Zhao, J. J., Fong, K. Y., Chan, Y. H., Tey, J., Dawood, S., Lee, S. C., Finn, R. S., Sundar, R., & Lim, J. S. J.
(2023). Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers, 15(18), 4558.
https://doi.org/10.3390/cancers15184558